| Health / Medical Topics |
Galeterone
An orally bioavailable small-molecule androgen receptor modulator and CYP17 lyase inhibitor with potential antiandrogen activity. Galeterone exhibits three distinct mechanisms of action: 1) as an androgen receptor antagonist, 2) as a CYP17 lyase inhibitor and 3) by decreasing overall androgen receptor levels in prostate cancer tumors, all of which may result in a decrease in androgen-dependent growth signaling. Localized to the endoplasmic reticulum (ER), the cytochrome P450 enzyme CYP17 (P450C17 or CYP17A1) exhibits both 17alpha-hydroxylase and 17,20-lyase activities, and plays a key role in the steroidogenic pathway that produces progestins, mineralocorticoids, glucocorticoids, androgens, and estrogens. (NCI Thesaurus)
YOU MAY ALSO LIKE
Galectin-9 (355 aa, ~40 kDa) is encoded by the human LGALS9 gene. This protein plays a role in galactoside binding and as…
Galectin-7 (136 aa, ~15 kDa) is encoded by the human LGALS7 and LGALS7B genes. This protein is involved in the mediation of…
Galectin-3 (250 aa, ~26 kDa) is encoded by the human LGALS3 gene. This protein plays a role in both antibody-mediated immunity and…
A calixarene-based compound and galectin-1 (Gal-1) inhibitor with potential anti-angiogenic and antineoplastic activities. Upon subcutaneous administration, galectin-1 inhibitor OTX008 binds Gal-1 which…
Galectin-1 (135 aa, ~15 kDa) is encoded by the human LGALS1 gene. This protein may play a role in modulating cell-cell and…
Constitutively and ubiquitously expressed by human LGALS8 Gene (S-Lectin Family), 316-amino acid 35.5-kD extracellular Galectin 8 contains two carbohydrate-binding (recognition) domains (CRDs)…
